FDA Warns: Ozempic Linked to Intestinal Blockages

The FDA has updated the label for Ozempic, an injectable diabetes drug, to include a warning about the potential side effect of intestinal blockage. The label change reflects reports of some users experiencing a condition called "ileus," which involves a blocking of the intestines. The FDA did not definitively establish a causal relationship between the drug's active ingredient, semaglutide, and the condition. This update follows a lawsuit from a woman who claims that Ozempic and its counterpart, Moujnaro, caused severe gastrointestinal side effects, including excessive vomiting and tooth loss. The drugmakers argue that these side effects are known and generally mild to moderate in severity. The label update may help protect the companies from legal action and inform patients about potential risks.